targeting acute and chronic inflammation. Our primary focus is on the development of monoclonal antibodies that target activation products of the complement system for application in life-threatening inflammatory diseases. We are a team of internationally recognized researchers and clinicians who have dedicated our careers to translating discoveries and expertise into new therapeutic concepts for clinical application.
C5a is a key player in many acute and chronic inflammatory processes. Thus, C5a is a highly attractive pharmacological target. However, a special Technology is required to effectively control this target.
InflaRx develops highly specific monoclonal antibodies targeting activation products of the complement system. InflaRx has made breakthrough discoveries in the area of anti-C5a antibody generation, resulting in a new class of highly selective antibodies with exceptional blocking activities.
InflaRx focuses on diseases with high unmet medical need. Vilobelimab, the company's first-in-class anti-human C5a monoclonal antibody is currently being developed in several chronic inflammatory diseases, as well as oncology and COVID-19-induced pneumonia.
The latest information on InflaRx share price with interactive charts, comparative analysis, historic figures and latest trade price is available here.
Gohibic (vilobelimab) - FDA has issued an emergency use authorization (EUA) to treat certain critically ill COVID-19 patients.
Our lead drug candidate, vilobelimab, is a first-in-class monoclonal antibody targeting the complement activation product C5a and is currently in clinical phase II development. read more ...
IFX-2 is a follow-on project to vilobelimab, in preclinical development. IFX-2 is a highly potent anti-complement C5a antibody with a higher humanization grade and altered pharmacokinetic properties. read more ...
Jena, Germany, May 11, 2023 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company developing an...
Jena, Germany, April 18, 2023 – InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a clinical-stage biopha...
Jena, Germany, April 14, 2023 – InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a clinical-stage biopha...
Jena, Germany, April 11, 2023 – InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a clinical-stage biopha...
Jena, Germany, April 11, 2023 – InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a clinical-stage biopha...
Jena, Germany, April 04, 2023 – InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical comp...
Jena, Germany, March 22, 2023 – InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical comp...
Jena, Germany, January 5, 2023 – InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical com...
Jena, Germany, December 21, 2022 – InflaRx N.V. (Nasdaq: IFRX) (the “Company” or “InflaRx”), a clini...
Jena, Germany, November 9, 2022 – InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical co...
